IL6 and cancer: For TTS, CRP ≥ 100mg/dL, elevated IL‐6, ≥ 2 organ comorbidities and decreased lymphocyte counts, were selected via univariate analyses (Figure S1B, Table S2) as possible relevant prognostic factors: after variable selection, an adjusted HR = 0.87 for cancer patients was observed (95% CI: 0.46‐1.65, P = .67; Table 4).